Arranta Bio, a CDMO focused on live therapeutic products and the human microbiome, has reported the mechanical completion of GMP suites at its new $100-million manufacturing facility in Watertown, Massachusetts.

Arranta is investing more than $100 million in 2020 to establish a multi-product, commercial-ready manufacturing facility that will supply live biotherapeutic products (LBPs) to microbiome innovator companies. Arranta is also expanding process development and GMP capacity at its early-clinical supply facility in Gainesville, Florida.

Last year (2019), Arranta Bio was formed to provide live biotherapeutic products for microbiome developers by bacterial fermentation, isolation, drying, and encapsulation. Arranta was founded by Mark Bamforth, founder and former CEO of Brammer Bio, a CDMO focusing on cell and gene therapies, which Thermo Fisher Scientific acquired for $1.7 billion in 2019. He is also the founder and former CEO of Gallus BioPharmaceuticals, a St. Louis, Missouri-based biologics CDMO, which was acquired by Patheon in 2014 and that subsequently became part of Thermo Fisher with Thermo Fisher’s $7.2-billion acquisition of Patheon in 2017. Later in 2019, Arranta Bio acquired Captozyme, a CDMO of process development and clinical contract manufacturing for microbiome companies.

Source: Arranta Bio